The Board of Directors of NextCell Pharma intends on resolving on a fully guaranteed preferential rights issue of approximately SEK 150 million

NextCell Pharma AB (“NextCell” or “the Company”) announces that the first patient with severe pneumonia, as a result of COVID-19 infection, has now been treated with ProTrans. The patient was hospitalized at Örebro University Hospital, where the phase 1b study ProTrans19+SE is in progress led by Principal Investigator Associate Professor Josefin Sundh. NextCell's drug candidate, ProTrans, is an immune- balancing cell therapy for the treatment of autoimmune diseases and inflammatory conditions. Patients with severe pneumonia as a result of by SARS-CoV-2 infection are at risk of rapid

Professor Edvard Smith, CMO NextCell Pharma AB ("NextCell" or the "Company") has written a review article in the Swedish Medical Journal (Läkartidningen) entitled "Gene therapy now comes in many medical specialties", together with Associate Professor Pontus Blomberg, Director of Operations; both at the Department of Laboratory Medicine, Karolinska Institutet; Karolinska Centre for Cell Therapy, Karolinska University Hospital, Stockholm. The main message of the article is that the development of gene therapy has been rapid, and more and more preparations are reaching patients and in many

NextCell Pharma AB (“NextCell”) announces today that they will present their findings from their Phase I/II study entitled “Wharton´s Jelly Derived Mesenchymal Stromal Cell Treatment of Adult Patients Diagnosed With Type I Diabetes” (NCT 03406585) at the International Society of Cell and Gene Therapy virtual conference 2021 (May 26[th]-28[th]). NextCell’s CSO, Dr. Lindsay Davies will attend the meeting and present a poster entitled “Protrans Wharton’s Jelly Mesenchymal Stromal Cells Preserve Beta Cell Function in Newly Diagnosed Type I Diabetes Patients – A Randomised, Double-Blinded,

NextCell Pharma AB (“NextCell”) announces today that both the Canadian and Swedish COVID-19 studies have been initiated and are now ready to include patients with severe pneumonia triggered by SARS-CoV-2 infection. The treatment is aimed at patients who are hospitalized and with a high risk of needing ventilatory support. ProTrans is given as a peripheral infusion. With the aim of reducing hyper-inflammation within the lungs. The goal of the treatment is to shorten hospital stay and time for rehabilitation, and to save lives. · ProTrans19 + CA, a randomized placebo-controlled phase-II study

NextCell Pharma AB (“NextCell”) announces today that the Swedish COVID-19 stuy has been initiated and is now ready to include patients with severe pneumonia triggered by SARS-CoV-2 infection. The treatment is aimed at patients who are hospitalized and with a high risk of needing ventilatory support. ProTrans is given as a peripheralinfusion. With the aim of reducing hyper-inflammation within the lungs. The goal of the treatment is to shorten hospital stay and time for rehabilitation and save lifes. The study will be performed at the University Hospital in Örebro in collaboration with the

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period September 1, 2020 - February 28, 2021 The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year. Second quarter (2020-12-01 until 2021-02-28) · Operating income amounted to SEK 1 007 846 (1 364 645). · Operating result amounted to SEK -8 148 299 (-4 228 449). · Earnings

NextCell Pharma AB (“NextCell”) has invited Professor Per-Ola Carlsson to present study design and rational for the pediatric study, ProTrans-Young. The trial, recently approved, is a phase I / II study with a total of 66 patients with newly diagnosed type-1 diabetes. The presentation will be broadcasted tomorrow, Wednesday April 28, at 14:00. Afterwards, there is an opportunity to ask questions to Professor Carlsson and NextCell's CEO and CSO. https://youtu.be/kE4POLMlXWA.

NextCell Pharma AB ("NextCell") announces today that Uppsala University Hospital and the principal investigator, Professor Per-Ola Carlsson, have been granted approval from the Medical Products Agency and the Swedish Ethical Review Authority to conduct a clinical drug trial with ProTrans™ to treat children and adolescents with type-1 diabetes. The study is a phase I / II study with a total of 66 patients. The first six patients treated will be evaluated for safety. The first six patients, three adolescents (12-18 years) and three children (7-11 years), will be treated and assessed for safety.